Levels of inflammatory markers (complement C3, Complement C4 and C-reactive protein) in smokers

African Journal of Biotechnology

Volumn 10, Issue 82, 2011, Pages 19211-19217

  Sanai, Mahrukh ^a   Hussain, Nageen ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

Body mass index; C reactive protein; Complement; Smokers

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4;

ADULT; ARTICLE; BODY MASS; CIGARETTE SMOKING; CLINICAL ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMORAL IMMUNITY; IMMUNODIFFUSION; INFLAMMATION; LATEX AGGLUTINATION TEST; MALE; MEN'S HEALTH; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SMOKING HABIT;

EID: 84855794687     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: 10.5897/AJB11.254     Document Type: Article

References (26)

1. Adil MM, Zubair M, Khan UA (2005). Prevalence of smoking in various cities of Pakistan. Rawal. Med. J. 30(2): 74-75.
2. Airoldi L, Magagnotti C, Colombi A, Pastorelli R, Fanelli R (2005). Differential protein expression profile in the urine of smokers and nonsmokers. Proc. Am. Assoc. Cancer. Res. p. 46.
3. Aral M, Ekerbicer HC, Celik M, Ciragil P, Mustafa G (2006). Research Communication: Comparison of effects of Smoking and Smokeless Tobacco "Maras Powder" Use on humoral Immune System Parameters. Mediator Inflammation, 20: 1-4.
4. Chaudry MA, Chaudry IA, Mahmood-ur-Rehman (2009). Prevalence of smoking among health care providers in tertiary care hospitals. Rawal. Med. J. 34: 40-42.
5. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F (2005). Complement C3 Is a risk factor for the development of diabetes. A population-based cohort study. Diabetes, 54(2): 570-575.
6. Ferns GAA (2001). C-reactive protein: a central player in atherogenesis or an epiphenomenon? Clin. Sci. 100: 357-358.
7. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C (2001). Smoking and CRP: results of Arnhem Elderly Study. CRP. 1: p. 18.
8. Jialal I, Devaraj S, Venugopal SK (2004). C-reactive protein: risk marker or mediator in atherothrombosis. Hypertension, 44(1): 6-11.
9. Kew RR, Ghebrehiwet B, Janoff A (1985). Cigarette Smoking can Activate the Alternate Pathway of Complement in Vitro by Modifying the Third Component of Complement. J. Clin. Invest. 75(3):1000-1007.
10. Labarrere CA, Zaloga GP (2004). C-reactive protein: From innocent bystander to pivotal mediator of atherosclerosis. Am. J. Med. 117(7): 499-507.
11. Loughlin JO, Lambert M, Karp I, McGrath J, Gray-Donald K, Barnett TA, Delvin EE, Levy E, Paradis G (2008). Association Between Cigarette Smoking and C-Reactive Protein in a Representative, Population-Based Sample of Adolescents. Nic. Tob. Res. 10(3): 525-532.
12. Moszczynski P, Zabinski Z, Moszczynski P, Rutowski J, Skowinski S, Tabarowski Z (2001). Immunological findings in cigarette smokers. Toxicol. Lett. 118(3):121-127.
13. Ohsawa M, Okayama A, Nakamura M, Onoda T, Kato K, Itai K, Yoshida Y, Ogawa A, Kawamura K, Hiramori K (2005). CRP levels are elevated in smokers but unrelated to the number of smokers and are decreased by long term smoking cessation in male smokers. Prevent. Med. 41(2): 651-656.
14. Perlstein TS, Lee RT (2006). Smoking, Metalloproteinases, and Vascular Disease. Arterioscler. Thromb. Vasc. Biol. 26(2): 250-256.
15. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR (2006). C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 61(1): 23-28.
16. Predict your risk of Future Disease. (Life Extension Magazine Report 2003).
17. Rawal N (2006). Complement. Ency. Resp. Med. pp. 546-552.
18. Robbins RA, Nelson KJ, Gossman GL, Koyama S, Rennard SI (1991). Complement activation by Cigarette Smoke. Lung. Cell. Mol. Physiol. 260: 254-259.
19. Saarni SE, Silventoinen K, Rissanen A, Sarlio-Lähteenkorva S, Kaprio J (2004). Intentional weight loss and smoking in young adults. Int. J. Obes. 28(6): 796-802.
20. Sin DD, Man SFP, McWilliams A, Lam S (2006). Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am. J. Respir. Crit. Care. Med. 173(5): 535-539.
21. Sopori M (2002). Effects of cigarette smoke on the immune system. Nat. Rev. Immunol. 2: 372-377.
22. Szeplaki G, Prohaszka Z, Duba J, Rugonfalvi-Kiss S, Karadi I, Kokai M, Kramer J, Fust G, Kleiber M, Romics L, Varga L (2004). Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis, 177(2): 383-389.
23. Tungtrongchitr R, Pongpaew P, Phonrat B, Supawan V, Chanjanakitskul S, Vudhivai N, Schelp FP (2002). The effect of cigarette smoking on ceruloplasmin and c3 complement: risk of cardiovascular disease (atherosclerosis). Asian. Pac. J. Aller. Imm. 20(1): 23-28.
24. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee JM, Heinrich E, Lee J, Sharma S, Dubinett SM (2008). Smoking and Lung Cancer. Proc. Am. Thor. Soc. 5: 811-815.
25. Yanbaeva DJ, Dentener MA, Cruetzberg EC, Wessling G, Wouters EFM (2007). Systemic Effects of smoking. Chest, 131(5): 1557-1566.
26. Yilmaz A, Akkaya E, Ece F, Karakurt Z, Baran A, Bayramgurler B (2001). Evaluation of Circulating Immune Complexes in Healthy Smokers. Turk. Res. J. 2(3): 32-35.